bluebird bio (NASDAQ:BLUE) Shares Down 4.2%

bluebird bio, Inc. (NASDAQ:BLUEGet Rating) shares were down 4.2% on Monday . The company traded as low as $6.81 and last traded at $6.84. Approximately 28,779 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 5,168,799 shares. The stock had previously closed at $7.14.

Analysts Set New Price Targets

Several analysts recently weighed in on BLUE shares. The Goldman Sachs Group upped their price target on bluebird bio from $2.00 to $3.00 and gave the stock a “sell” rating in a research note on Friday, August 19th. SVB Leerink increased their price target on shares of bluebird bio from $8.00 to $10.00 and gave the company a “market perform” rating in a report on Thursday, August 18th. Barclays upgraded shares of bluebird bio from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $3.00 to $5.00 in a report on Friday, August 5th. Raymond James upgraded bluebird bio from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research note on Tuesday, August 2nd. Finally, Morgan Stanley cut their target price on bluebird bio to $3.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 17th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.08.

bluebird bio Price Performance

The firm has a market capitalization of $511.32 million, a PE ratio of -0.80 and a beta of 1.12. The firm has a 50-day simple moving average of $5.60 and a 200-day simple moving average of $4.67.

bluebird bio (NASDAQ:BLUEGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.31) by $0.02. The company had revenue of $1.52 million for the quarter, compared to the consensus estimate of $6.47 million. bluebird bio had a negative net margin of 2,141.34% and a negative return on equity of 130.19%. Equities analysts expect that bluebird bio, Inc. will post -4.66 earnings per share for the current year.

Insider Transactions at bluebird bio

In other bluebird bio news, CEO Andrew Obenshain sold 21,805 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the sale, the chief executive officer now owns 247,131 shares in the company, valued at $1,084,905.09. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Jason Cole sold 7,448 shares of the stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $32,696.72. Following the completion of the sale, the insider now directly owns 203,740 shares of the company’s stock, valued at $894,418.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Andrew Obenshain sold 21,805 shares of the firm’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $95,723.95. Following the sale, the chief executive officer now owns 247,131 shares in the company, valued at $1,084,905.09. The disclosure for this sale can be found here. Insiders have sold 44,805 shares of company stock worth $213,636 in the last 90 days. 2.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On bluebird bio

A number of institutional investors have recently bought and sold shares of BLUE. Advisor Group Holdings Inc. lifted its holdings in shares of bluebird bio by 24.4% in the fourth quarter. Advisor Group Holdings Inc. now owns 18,058 shares of the biotechnology company’s stock worth $180,000 after buying an additional 3,543 shares in the last quarter. Northern Trust Corp lifted its stake in bluebird bio by 0.3% in the 4th quarter. Northern Trust Corp now owns 719,985 shares of the biotechnology company’s stock worth $7,193,000 after purchasing an additional 2,348 shares in the last quarter. ProShare Advisors LLC lifted its stake in bluebird bio by 6.7% in the 4th quarter. ProShare Advisors LLC now owns 24,632 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 1,538 shares in the last quarter. Bank of America Corp DE lifted its stake in bluebird bio by 513.4% in the 4th quarter. Bank of America Corp DE now owns 694,929 shares of the biotechnology company’s stock worth $6,942,000 after purchasing an additional 581,642 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of bluebird bio by 34.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 453,869 shares of the biotechnology company’s stock worth $4,535,000 after buying an additional 116,621 shares in the last quarter. Hedge funds and other institutional investors own 78.25% of the company’s stock.

bluebird bio Company Profile

(Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Recommended Stories

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.